Welcome to our dedicated page for Vor Biopharma news (Ticker: VOR), a resource for investors and traders seeking the latest updates and insights on Vor Biopharma stock.
Vor Biopharma Inc., trading under the ticker symbol VOR, is at the forefront of cell and genome engineering, specifically focusing on hematopoietic stem cells (HSCs). Headquartered in Cambridge, Massachusetts, Vor Bio aims to revolutionize the treatment of hematological cancers, particularly acute myeloid leukemia (AML). The company’s pioneering platform involves engineering hematopoietic stem cells (eHSCs) to generate healthy and functional cells with beneficial modifications. These modifications protect the blood and bone marrow from the adverse effects of antigen-targeted therapies while leaving cancer cells vulnerable.
Key Products and Innovations:
- VOR33 (Trem-cel) - Vor Bio’s lead program, a CRISPR/Cas9 genome-edited allogeneic HSC transplant that lacks the CD33 protein. This product is designed to replace standard transplants for AML patients and potentially other blood cancers.
- VCAR33ALLO - A CD33-directed CAR-T cell therapy derived from healthy transplant donor cells. This approach aims to provide more potent and durable responses in the post-transplant setting without on-target toxicity.
Recent Achievements and Collaborations:
- Secured a non-exclusive worldwide license from Editas Medicine for ex-vivo Cas9 gene-edited HSC therapies.
- Partnership with Janssen for the preclinical development of CD33-deleted allografts and their synergistic effects with Janssen's CD33-targeted immunotherapy candidate.
Clinical Trials and Research:
- VBP101 Clinical Trial - Ongoing Phase 1/2a study of trem-cel in AML patients, showing promising engraftment results and hematologic protection.
- VCAR33ALLO Clinical Trial (VBP301) - A Phase 1/2 study involving CAR-T cell therapy derived from healthy transplant donors, showing initial successful dosing and manufacturing capabilities.
Financial Updates: In its latest quarterly report, Vor Bio announced positive financial outcomes, including an extended cash runway into the second half of 2025. The company is focused on executing its clinical trials and expanding its platform to include additional innovative therapies.
Future Outlook: Vor Bio is set to present at major scientific conferences, including the American Society of Hematology (ASH) Annual Meeting, where it will share significant preclinical and clinical data. The company is also looking forward to additional data releases from its clinical trials by year-end, which could further validate their treatment system for AML.
For more updates, visit www.vorbio.com.
Vor Biopharma (Nasdaq: VOR) and Abound Bio have entered a strategic collaboration to develop CAR-T treatments combined with Vor's engineered hematopoietic stem cell (eHSC) platform, focused on treating acute myeloid leukemia (AML) and other blood cancers. The partnership aims to enhance multi-targeted CAR-T therapies while protecting healthy cells, aligning with Vor's mission of creating effective cancer treatments. Financial terms of the collaboration were not disclosed.
Vor Biopharma, a pioneering cell therapy company, announced that its President, Robert Ang, and CFO, Nathan Jorgensen, will present at two key conferences. The Jefferies Virtual Healthcare Conference is scheduled for June 1, 2021, at 4:00 PM ET, followed by the Goldman Sachs 42nd Annual Global Healthcare Conference on June 9, 2021, at 9:40 AM ET. These presentations will showcase Vor's innovative engineered hematopoietic stem cell therapies aimed at treating cancer. Live webcasts will be available on the company's website.
Vor Biopharma (Nasdaq: VOR) announced the clearance of its clinical trial application (CTA) for VOR33 in acute myeloid leukemia (AML) by Health Canada, marking a significant regulatory milestone. The company successfully raised $203.4 million through its initial public offering (IPO), enhancing its cash position to $262.6 million as of March 31, 2021. In addition, Vor plans to present critical findings regarding VOR33 at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, supporting its upcoming Phase 1/2a trial set to begin in Q2 2021.
Vor Biopharma (Nasdaq: VOR) announces two presentations at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting on May 11, 2021. The presentations will focus on VOR33, an engineered hematopoietic stem cell (eHSC) clinical candidate targeting acute myeloid leukemia. The oral presentation by Dr. John Lydeard will detail the CRISPR/Cas9 technology used in VOR33, while a poster will assess off-target editing. These developments aim to enhance treatment efficacy and patient outcomes.
Vor Biopharma (Nasdaq: VOR) announced that the FDA accepted the IND for VOR33, its lead eHSC product candidate targeting acute myeloid leukemia (AML). The company successfully completed an IPO, raising $203.4 million, enhancing its financial standing. Cash at year-end 2020 was $48.5 million, with R&D expenses rising to $31.6 million due to increased preclinical studies. Vor reported a net loss of $43.3 million for 2020. Upcoming milestones include the initiation of the Phase 1/2a trial for VOR33 in Q2 2021 and initial data expected in late 2021 or early 2022.
Vor Biopharma (Nasdaq: VOR), a leader in engineered hematopoietic stem cell therapies, announced its participation in the Barclays Global Healthcare Conference, set for March 9-11, 2021. CEO Robert Ang and CFO Nathan Jorgensen will present on March 11 at 3:00 p.m. E.T. Interested parties can access the live webcast through the Investors section of Vor's website. Vor Biopharma is dedicated to innovating cancer treatments, focusing on creating treatment-resistant transplants that enhance targeted therapies while protecting healthy cells.
Vor Biopharma (Nasdaq: VOR), a leader in engineered hematopoietic stem cell (eHSC) therapies for cancer treatment, will participate in the Cowen 41st Annual Health Care Conference from March 1-4, 2021. CEO Robert Ang and CFO Nathan Jorgensen are set to present on March 4 at 1:30 p.m. E.T. The company focuses on developing treatment-resistant transplants that enhance the effectiveness of targeted therapies, allowing for the selective destruction of cancer cells while preserving healthy tissue.
Vor Biopharma (Nasdaq: VOR) has successfully closed its initial public offering (IPO), issuing 9,828,017 shares of common stock, with an additional 1,474,202 shares sold due to underwriter options. The shares, priced at $18.00 each, generated gross proceeds of approximately $203.4 million. Trading began on February 5, 2021. This IPO enhances Vor's financial position as it continues to develop engineered hematopoietic stem cell therapies targeting cancer treatment.
PureTech Health announces that its founded entity, Vor Biopharma, has priced its initial public offering (IPO) of 9,828,017 shares at $18.00 each, raising approximately $176.9 million before expenses. The shares are slated to start trading on Nasdaq under the symbol VOR on February 5, 2021, with the offering expected to close by February 9, 2021. Following the IPO, PureTech will hold 3,207,200 shares of Vor, representing about 9.0% of its outstanding shares.
Vor Biopharma (Nasdaq: VOR), a cell therapy firm, announced the pricing of its IPO, offering 9,828,017 shares at $18.00 per share. This will raise approximately $176.9 million before deductions. The underwriters have a 30-day option to purchase an additional 1,474,202 shares. Trading is set to start on February 5, 2021, with the offering closing on February 9, 2021. Goldman Sachs and others are the joint book-running managers. Registration statements have been filed with the SEC.
FAQ
What is the current stock price of Vor Biopharma (VOR)?
What is the market cap of Vor Biopharma (VOR)?
What is Vor Biopharma Inc. known for?
What are the main products of Vor Biopharma Inc.?
Where is Vor Biopharma Inc. located?
What recent achievements has Vor Biopharma Inc. made?
What clinical trials are currently being conducted by Vor Biopharma Inc.?
What is the potential impact of Vor Biopharma Inc.'s platform?
How can I stay updated on Vor Biopharma Inc.'s progress?
What financial updates were provided by Vor Biopharma Inc. recently?
What upcoming milestones is Vor Biopharma Inc. expecting?
What collaborations has Vor Biopharma Inc. entered into?
